Shares of Achillion Pharmaceuticals Inc., a company that is developing a competing hepatitis C therapy, rose 24 cents, or 4.1 percent, to $6.14.
More Safety Info:
- Concerns about motorcycle customization
- UMass survey finds parking, safety top downtown businesses’ list of concerns
- APNewsBreak: Prosecutors say Alpha improving safety at mines …
- FDA revisits safety of Arena Pharma’s diet pill
- Possible pilot shortage raises safety concerns